Phaseline

Targets › PRKDC

PRKDC (DNA-dependent protein kinase catalytic subunit): drug programs, companies and trials

1 program from 1 company in 9 trials: 9 Phase 1; Oncology; next expected readout Dec 2026.

Serine/threonine-protein kinase that acts as a molecular sensor for DNA damage. Involved in DNA non-homologous end joining (NHEJ) required for double-strand break (DSB) repair and V(D)J recombination. (UniProt, P78527)

Open in Phaseline: the race on PRKDC, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Cancer Institute (NCI)Peposertib
DNA-PKcs inhibitor
PRKDC, ATMPhase 1Advanced Head and Neck Squamous Cell Carcinoma; Neuroendocrine Neoplasm; Metastatic Castration-Resistant Prostate Carcinoma; Metastatic Dedifferentiated Liposarcoma …Dec 2026

Conditions

Advanced Head and Neck Squamous Cell Carcinoma (1) Neuroendocrine Neoplasm (1) Metastatic Castration-Resistant Prostate Carcinoma (1) Metastatic Dedifferentiated Liposarcoma (1) Endometrial High Grade Endometrioid Adenocarcinoma (1) Recurrent Acute Myeloid Leukemia (1) Locally Advanced Malignant Solid Neoplasm (1) Locally Advanced Pancreatic Adenocarcinoma (1) Advanced Malignant Solid Neoplasm (1)

Modalities

mixed (1)

Companies

National Cancer Institute (NCI) (1)

Related targets

ATM (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.